Loading...
•
Mar 31, 2024
Exact Sciences Q1 2024 Earnings Report
Exact Sciences reported a revenue increase driven by growth in screening and precision oncology segments.
Key Takeaways
Exact Sciences announced first-quarter 2024 results with a total revenue of $638 million, a 6% increase compared to the same period in 2023. The company maintains its full-year 2024 revenue and adjusted EBITDA guidance.
Total first-quarter revenue reached $638 million, reflecting a 6% increase year-over-year.
Screening revenue amounted to $475 million, a 7% increase compared to the previous year.
Precision Oncology revenue was $163 million, marking a 5% increase.
The company maintains full-year 2024 revenue and adjusted EBITDA guidance.
Revenue by Segment
Forward Guidance
The company has maintained its revenue guidance of $2.810-$2.850 billion during 2024.
Positive Outlook
- Screening revenue of $2.155-$2.175 billion.
- Precision Oncology revenue of $655-$675 million.
- Maintained full-year revenue guidance.
- Maintained adjusted EBITDA guidance.
- Continued investment in innovative solutions.
Challenges Ahead
- Potential impacts from macroeconomic conditions.
- Risks associated with development and commercialization of new products.
- Competition for products and services.
- Reliance on certain suppliers.
- Potential effects of judicial, executive, or legislative actions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...